Encure Bio-Executive Team
Dr. JC Bose Rajendran, Ph.D.
Founder & CEO
Encure founder Dr. JC Bose Rajendran brings 15+ years of experience spanning AI-enabled drug discovery and advanced delivery platform development across cardiovascular disease, cancer, and rare disorders.
A pharmacist and biomedical engineer (BPharm/MPharm in Pharmaceutical Sciences; PhD in Bioengineering), he completed postdoctoral training in nanomedicine, molecular imaging, and AI-enhanced drug delivery at Stanford University, UT Southwestern Medical Center, and the Masonic Medical Research Institute (MMRI), where he co-invented the eSENTs platform for cardio-splenic immune modulation after myocardial infarction.
He has held leadership roles at Sanofi, LG Life Sciences, Serina Therapeutics (LNP programs), and Jurata Thin Film, advancing AI-optimized nanocarriers, lipid nanoparticles, and organ-targeted delivery systems.
At Encure, he leads development of SWATI-AI, a cardio-native platform integrating quantum-enhanced modeling, human cardiac organoids, and advanced nanoengineering to discover targets and design precision cardiovascular therapies.
Dr. Jason R. McCarthy, Ph.D.
Co‑Founder & Scientific Advisor
Dr. McCarthy is Professor of Biomedical Research and Translational Medicine and Scientific Operations Director at the Masonic Medical Research Institute (MMRI), where he leads multidisciplinary R&D bridging nanomedicine, molecular imaging, and translational cardiovascular therapeutics.
His work focuses on designing targeted nanomaterials and imaging agents to detect and modulate disease processes in vivo, with an emphasis on cell-specific delivery and clinically actionable biology.
Previously, he served as Assistant Professor of Radiology at Harvard Medical School and held a long-standing appointment at Massachusetts General Hospital in Radiology, building a track record at the interface of imaging science, chemistry, and translational medicine.
In addition to research leadership, he contributes to innovation and workforce development through board and advisory roles, including Secretary of the Board of Directors for Three Pillars Innovation, Inc., and advisory board memberships spanning SUNY Polytechnic Institute, SUNY Upstate Medical University, and regional career-pathway programs.
At Encure, Dr. McCarthy advises on the discovery-to-delivery strategy for immune-mediated cardiovascular disease, aligning AI-driven target discovery with scalable, mechanism-first delivery platform development.
Dr. Ramasamy Paulmurugan, Ph.D.
Scientific Advisor
With 25+ years in molecular imaging, nanomedicine, and gene therapy, Ramasamy Paulmurugan, Ph.D. is a leading expert in targeted drug delivery, RNA therapeutics, Molecular cell biology and cancer biology.
He is a Professor (Research) of Radiology at Stanford’s Molecular Imaging Program, where he directs the Cellular Pathway Imaging Laboratory and develops multimodal imaging and nano‑RNA platforms for hard‑to‑treat cancers.
He also mentored Encure founder Dr. JC Bose as a postdoctoral fellow at School of Medicine, Stanford University, training him in engineered nanotechnology for targeted delivery of drug and gene therapeutics in triple negative breast cancer, GBM and HCC.
Dr. Lakshman Tamil, Ph.D.
Scientific Advisor
With 35+ years in AI for healthcare, medical imaging, and IoT diagnostics, Dr. Lakshman Tamil Ph.D. is a Professor of Electrical and Computer Engineering at UT Dallas, where he leads research in quantum machine learning and AI-driven clinical decision systems.
A Fellow of the National Academy of Inventors, OPTICA, and the Electromagnetics Academy, he has pioneered automated AI systems for breast cancer detection (MedCognetics) and cardiac arrhythmia monitoring (Cardiocognetics), achieving >95% diagnostic accuracy and commercializing these innovations.
Trained in electrical engineering (PhD, University of Rhode Island) and mathematics, Dr. Tamil brings deep expertise in translating AI research into FDA-pathway clinical products.
At Encure Biotherapeutics, Dr. Tamil guides the integration of quantum-enhanced AI modeling and machine learning into cardiovascular drug discovery and precision medicine platforms.